In this study, we will prospectively assess the association between serum CK and response to standard antihypertensive drugs (calcium blockers or monotherapy with other antihypertensive drugs according to the policy of the general practitioner).
ID
Source
Brief title
Condition
- Vascular hypertensive disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The difference in blood pressure response after 3 weeks of treatment in
relation to baseline serum CK.
Secondary outcome
The difference between serum CK activity at baseline and after 3 weeks of
treatment with antihypertensive drugs.
Background summary
Failure of hypertension treatment is a major clinical issue. We have reported
evidence that creatine kinase (CK) increases blood pressure through greater
sodium retention and cardiovascular contractility, by rapidly providing ATP for
these functions. Furthermore, we found in a cross-sectional setting that CK was
the main predictor of treatment failure (adjusted OR 3.7; 95% CI 1.2 to 10.9)
in the population, independent of age, sex, BMI, fasting glucose, ethnicity, or
education level.
Study objective
In this study, we will prospectively assess the association between serum CK
and response to standard antihypertensive drugs (calcium blockers or
monotherapy with other antihypertensive drugs according to the policy of the
general practitioner).
Study design
Observational study
Study burden and risks
The extra burden for the participant besides the regular first line patient
care is the draw of 2 extra tubes of blood.
The antihypertensive treatment and diagnostic examinations (blood draw, EKG,
urine analysis) are all clinical standards within first line care.
Venapunction may induce a vasovagal collaps. We expect little side effects for
the standard first line treatment. Side effects that may occur with calcium
blockers are headache, oedema, redness of the face, obstipation, and fatigue.
Then the medication will be switched to another drug in accord with the general
practitioners protocol.
Meibergdreef 9
Amsterdam 1105 AZ
NL
Meibergdreef 9
Amsterdam 1105 AZ
NL
Listed location countries
Age
Inclusion criteria
Ambulatory adult subjects age 18-60 years, with newly detected hypertension stage I and II in primary care (SBP/DBP * 140/90 and SBP/DBP < 180/110 on at least two consecutive visits), after drie days of rest, otherwise healthy, without clinical or laboratory evidence of muscle damage.
Exclusion criteria
No rest during the last 3 days, treated hypertension, severe (SBP * 180 mm Hg) hypertension, secondary hypertension, (history of) cardiovascular disease including TIA and stroke, myocardial infarction, angina, BMI>/= 30 kg/m2, diabetes mellitus, lipid spectrum abnormalities, thyroid, kidney, or liver abnormalities; CK-increasing drugs including statins; neuromuscular or endocrine disorders; vasculitis; HIV infection; infectious hepatitis.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL40748.018.12 |